Related Experiment Videos
Lesion visualization by targeted computed tomography liver enhancement in dogs
F T Lee1, I A Sproat, A H Rappe
1University of Wisconsin Hospital and Clinics, Department of Radiology, Madison 53792-3252, USA.
Academic Radiology
|June 1, 1995
Summary
New liver-specific contrast agents show promise for improving computed tomography (CT) lesion detection. These targeted agents enhance lesion visibility and edge definition compared to standard intravenous contrast.
Area of Science:
- Radiology
- Medical Imaging
- Hepatology
Background:
- Liver lesion detection is crucial for diagnosis and treatment.
- Current computed tomography (CT) contrast agents have limitations in enhancing lesion visibility.
Purpose of the Study:
- To evaluate the potential benefits of liver-specific targeted CT contrast agents.
- To compare targeted agents with standard intravenous contrast for lesion detection.
Main Methods:
- A pilot study was conducted on eight dogs with induced liver infarcts.
- CT scans were performed using unenhanced, intravenous contrast-enhanced (IVCE), CT arterial portography (CTAP), and targeted liver enhancement with iodipamide ethylester (IDE) particles.
- Quantitative and subjective analyses assessed liver-to-lesion density differences and edge sharpness.
Main Results:
- Targeted IDE contrast agents significantly improved liver-to-lesion density differences compared to unenhanced scans.
- IDE and CTAP demonstrated superior lesion edge definition compared to standard IVCE.
- IDE-enhanced scans provided the best subjective and quantitative edge definition.
Conclusions:
- Liver-specific targeted contrast agents hold potential for enhancing lesion visibility in liver imaging.
- These agents improve lesion edge definition and attenuation differences.
- Further research in animal tumor models and clinical trials is warranted.